BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 11, 2014

Primary Completion Date

October 18, 2019

Study Completion Date

June 1, 2023

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

BI 836845

DRUG

Enzalutamide

DRUG

Enzalutamide

Trial Locations (27)

100

National Taiwan University Hospital, Taipei

10065

NewYork-Presbyterian/Weill Cornell Medical Center, New York

11217

Taipei Veterans General Hospital, Taipei

28007

Hospital General Universitario Gregorio Marañón, Madrid

28034

Hospital Ramón y Cajal, Madrid

40705

Taichung Veterans General Hospital, Taichung

46009

Instituto Valenciano de Oncología, Valencia

48201

Karmanos Cancer Institute, Detroit

97239

Oregon Health and Sciences University, Portland

169610

National Cancer Centre Singapore, Singapore

258499

OncoCare Cancer Centre, Singapore

308433

Tan Tock Seng Hospital, Singapore

999077

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

3075 EA

Erasmus MC - Daniel den Hoed, Rotterdam

5042 AD

Tweesteden Ziekenhuis, locatie Tilburg, Tilburg

135-710

Samsung Medical Center, Seoul

138-736

Asan Medical Center, Seoul

08035

Hospital Vall d'Hebron, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

08041

Hospital Santa Creu i Sant Pau, Barcelona

08908

Hospital Duran i Reynals, L'Hospitalet de Llobregat

CH63 4JY

The Clatterbridge Cancer Centre, Bebington, Wirral

CF14 2TL

Velindre Cancer Centre, Cardiff

M20 4BX

The Christie Hospital, Manchester

OX3 7LE

Churchill Hospital, Oxford

SM2 5PT

The Royal Marsden Hospital, Sutton, Sutton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY